This market resolves to Yes if the findings of a phase III trial for elraglusib combined with chemotherapy for pancreatic cancer are publicly released by June 30, 2026. The information must be published in a peer-reviewed journal or announced as a press release by a credible institution involved in the trial.
this feels like a long shot, pancreatic cancer research takes ages and this is still in trial, i'm not confident we'll see results that soon.
Rationale:The comment accurately reflects the typical duration of clinical trials and the recent publication of phase 2 results, making the prediction of phase 3 results by June 2026 unlikely. The argument is logically sound and directly relevant to the market question, with a balanced use of logic and emotion.
The timeline for publishing phase III trial results for elraglusib seems unclear at this point. Typically, these studies can take years before we see a final publication, especially when it comes to something as complex as pancreatic cancer. Yes, there might be pressure to release results by mid-2026, but multiple factors can delay this, such as patient recruitment issues or regulatory hurdles. It feels risky to assume a publication by this specific date; I’m leaning toward a later release. I wonder if the current market price considers these delays or if it’s too optimistic in light of cancer’s inherently unpredictable nature.
Rationale:The comment provides a reasonable assessment of the uncertainties surrounding the publication timeline for the phase III trial results of elraglusib, acknowledging potential delays due to various factors. While the claims are mostly accurate, the mention of 'pressure to release results' lacks specific evidence, leading to a slightly lower score for Fact Check. The comment is relevant and free from logical fallacies, with a balanced approach between logical reasoning and emotional context, justifying the weights assigned.
idk about this price tbh, seems way too optimistic rn. phase III trials are always a gamble and pancreatic cancer’s tough, so i’d bet against this hitting by 2026.
Rationale:The comment accurately reflects the uncertainty and challenges of phase III trials, especially for pancreatic cancer, which is known to be difficult to treat. The recent positive phase II results for elraglusib suggest some optimism, but the comment's skepticism is reasonable given the historical difficulty of treating this cancer type. The argument is mostly logical, though it could benefit from more detailed reasoning. The relevance is high as it directly addresses the market question.
Not sure why this market is hovering so low, phase III data usually has decent hype. I'm leaning yes, but this could swing.
Rationale:The comment accurately reflects the current hype around phase III data, supported by recent positive phase II results. However, it lacks specific evidence or data about the phase III trial's progress, which slightly lowers the fact check score. The comment is relevant to the market question, but the reasoning is somewhat speculative, affecting the logic/emotion balance.
nah, it feels a bit risky to bet on this one, we all know how slow these trial results can be, i'm not convinced it'll drop by that date.
Rationale:The comment expresses skepticism about the timing of the trial results, which is a relevant concern given the history of delays in clinical trials. While the statement is mostly accurate, it lacks specific evidence to support the claim about the trial's timeline, leading to a slightly lower fact check score. The weights reflect a balance between relevance and the need for logical reasoning without falling into emotional appeal.
i'm skeptical this will even make it to phase III by then, the price feels too optimistic. pancreatic cancer trials always have that ‘slow to publish’ vibe.
Rationale:The comment expresses skepticism about the timeline for the phase III trial publication, which is a relevant concern given the historical context of pancreatic cancer trials. While the claim about the 'slow to publish' nature of these trials is somewhat accurate, it lacks specific evidence to support the assertion about elraglusib. The weights reflect a balance between relevance and the need for factual support, as the comment is primarily an opinion based on general trends rather than specific data.
i dunno, that timeline feels super optimistic considering how slow these trials usually move. i wouldn't bet on it coming out that soon.
Rationale:The comment expresses skepticism about the timeline for the trial results, which is a reasonable perspective given the historical pace of clinical trials. However, it lacks specific factual references to support the claim of optimism. The comment is logically sound and relevant to the market question, but it leans slightly on emotional appeal. The weights reflect a balanced approach, emphasizing relevance and logical coherence while acknowledging the need for factual backing.
honestly think this trial is gonna hit some delays, pancreatic cancer research is rough, rn i wouldn’t be surprised if it slips to 2027. price feels kinda optimistic, ngl.
Rationale:The comment expresses a reasonable concern about potential delays in the trial, which is a valid point given the complexities of pancreatic cancer research. While it lacks specific data to support the claim of delays, it reflects a cautious perspective on the timeline. The weights reflect a balance between relevance and the need for factual support, given the speculative nature of the comment.
I think there's a decent chance this trial will get published on time. Phase III trials can take a while, but the urgency around pancreatic cancer may speed things up. I'd lean toward yes.
Rationale:The comment suggests a possibility of timely publication due to urgency, but the search results indicate that the Phase 2 results were only recently published in April 2026, and the Phase 3 trial is merely planned. This makes a publication by June 30, 2026, unlikely. The argument is mostly logical and relevant, but the factual basis is weak due to the timeline discrepancy.
the way cancer trials go, i wouldn’t be surprised if they blow past that date, nothing is ever straightforward with this stuff.
Rationale:The comment suggests skepticism about the timely publication of Phase 3 trial results, which is a reasonable concern given the complexity of clinical trials. However, it lacks specific evidence or data to support this claim. The Phase 2 results were published, indicating progress, but this does not directly predict Phase 3 outcomes. The comment is relevant and free from major fallacies, but it leans on general skepticism rather than detailed analysis.